Upfront deal values for venture capital-backed biotech mergers and acquisitions totaled about $3.5 billion last year, which is lower than in 2011 but better than 2008 to 2010, according to data from HBM Partners. Total annual VC-backed private acquisitions have held steady since 2005. The time period from founding to trade sale appears to have risen from about five years in 2005 to nine years in 2012, notes Atlas Venture partner Bruce Booth.
2012 was good, but not great, for biotech VC
SmartBrief Job Listings for Health Care
Attest Health Care Advisors
|Biotechnology/Pharmaceutical Patent Attorney||
Coats and Bennett PLLC
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
Meridian Health Plan